MONTREAL and AUSTIN, Texas and HAMILTON, Ontario, Feb. 20, 2019 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“), a Canadian specialty pharmaceutical company focused on acquiring, in-licensing, selling and marketing innovative pharmaceutical products, today announced it has entered into a secured loan and exclusive License Agreement with privately-held Triumvira Immunologics Inc. (“Triumvira“). The US$5 million secured loan has a term of 1 year and will enable Triumvira to accelerate activities to bring its innovative lead program into the clinic. In addition, Triumvira shall grant Knight an exclusive license to commercialize Triumvira’s future approved products for Canada, Israel, Mexico, Colombia and for TAC01-CD19 for Israel, Mexico, Brazil and Colombia.
“We are excited to help Triumvira accelerate development of their novel platform for engineering T cells to attack cancer,” said Jonathan Ross Goodman, Chief Executive Officer of Knight.
“We are thrilled both with this Knight solution to our short-term funding need and in having Knight as our proven successful Canadian, Israeli and South American distribution partner,” said Dr. Paul Lammers, President and Chief Executive Officer.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.gudknight.com or www.sedar.com.
About Triumvira Immunologics Inc.
Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Triumvira’s proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the Major Histocompatibility Complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer. With operations spanning North America, Triumvira’s corporate offices are in Austin, Texas, and its research facilities are in Hamilton, Ontario.
Knight Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2017. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events, except as required by law.
For more information please contact: